Application by Icahn Group to cease trade the poison pill of Lions Gate Entertainment, in the context of Icahn's hostile take-over bid for Lions Gate.
Osler successfully represented Icahn Group in its application to the British Columbia Securities Commission to cease trade of the poison pill implemented by the board of directors of Lions Gate Entertainment Corp. as a defensive tactic against the Icahn Group’s hostile take-over bid for Lions Gate.
The expedited appeal by Lions Gate to the British Columbia Court of Appeal, the first-ever Canadian appeal in a poison pill case, was dismissed from the bench (2010).
Icahn Associates Corp., also known as Icahn Group, is a privately owned hedge fund sponsor. The firm invests in the public equity and hedging markets of the United States. It was founded in 1985 and is based in New York City.
Osler, Hoskin & Harcourt LLP represented Icahn Associates Corp with a team consisting of Mark Gelowitz, Allan Coleman (Litigation), Shuli Roda (Competition Law/Foreign Investment Group), Rosalind Hunter, and Donald Ross (Corporate).
Team
Partner, Competition/Antitrust and Foreign Investment
Chair, Diversity Committee, Toronto
Partner, Disputes, Toronto
Partner, Disputes, Toronto
Partner, Corporate, Toronto
